Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients With High PD-L1
Clinical study of ivonescimab for first-line treatment of metastatic NSCLC patients with high PD-L1. Evaluating overall survival and progression free survival.
Non-Small Cell Lung Cancer
BIOLOGICAL: Ivonescimab Injection|BIOLOGICAL: Pembrolizumab Injection
Overall Survival (OS), Up to approximately 36 months|Progression free survival (PFS), Up to approximately 36 months
Objective response rate (ORR), Up to approximately 36 months|Disease control rate ( DCR), Up to approximately 36 months|Duration of response (DoR), Up to approximately 36 months|Adverse Events (AE): incidence and severity of adverse events (AEs) and clinically significant abnormal laboratory test results, [Time Frame: From the subject signs the ICF to 30 days (AE) and 90 days (SAE related to ivonescimab/pembrolizumab ) after the last dose of study treatment or initiation of other anticancer therapy, whichever occurs first, Up to approximately 24 months.
Clinical study of ivonescimab for first-line treatment of metastatic NSCLC patients with high PD-L1. Evaluating overall survival and progression free survival.